Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BAG1
REST API REST API
Homo sapiens
BAG1 is differentially expressed in 334 experiments: 155 organism parts: testis, bone marrow, ... (153 more);, 215 disease states: normal, glioblastoma, ... (213 more);, 89 cell types 497 cell lines 47 compound treatments and 87 other conditions.
Orthologs Bag1 (Mus musculus)   BAG1 (Gallus gallus)   Q148J7_BOVIN (Bos taurus)   BAG1 (Danio rerio)   ENSCING00000012405 (Ciona intestinalis)   Bag1 (Rattus norvegicus)   bag1 (Xenopus laevis)   BAG1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term neuron differentiation, cytosol, protein binding, apoptosis, cytoplasm, negative regulation of apoptosis, chaperone binding, response to stress, anti-apoptosis, positive regulation of transcription from RNA polymerase II promoter, nucleus, response to drug, perinuclear region of cytoplasm, phosphoprotein binding, mitochondrion, response to lithium ion, response to nicotine, positive regulation of neuron apoptosis, response to organic cyclic compound
InterPro Term Ubiquitin_supergroup, Ubiquitin, Molecular_chp_reg_BAG_1, BAG_domain
UniProt Accession Q99933, C9J9Y9, C9JYK5, Q5VZF1, F1LLU6, E2QRM7
Search EB-eye ENSG00000107262
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-MTAB-37, E-GEOD-2509, E-GEOD-18005
HL-60
1
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258, E-GEOD-96
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HCC1143
2
E-MTAB-37, E-MTAB-62
HCC38
2
E-MTAB-37, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
491 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21909, ... (49 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
fibroblast
2
E-GEOD-3204, E-GEOD-3920
stromal cell
1
2
E-GEOD-10797, E-GEOD-1460, E-MEXP-2034
mast cell
1
E-GEOD-3982
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-12254, ... (68 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-1331
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
colorectal carcinoma
2
E-GEOD-23878, E-MTAB-37
sarcoma
2
E-GEOD-2719, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
209 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (32 experiments)

Factor Value U/D Experiments
none
5
8
E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1601, E-MEXP-1958, ... (13 experiments)
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
unknown
1
E-GEOD-7307
HMB-PP (phosphoantigen)
1
E-MEXP-1601
control - untreated
1
E-GEOD-7216
41 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-21374, E-GEOD-4619, E-GEOD-1563, ... (13 experiments)

Clinical treatment
studied in E-GEOD-6532

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, E-MEXP-958, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-2509, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-763, E-MEXP-1996, E-TABM-1029, E-GEOD-3494, E-GEOD-17476, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (37 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, ... (8 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, E-GEOD-20037 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-GEOD-1676, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-22541, E-GEOD-7307, E-GEOD-1295 ... (5 experiments)

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.394 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM